Doxils - the first fda-approved nano-drug: From basics via cmc, cell culture and animal studies to clinical use

Yechezkel Chezy Barenholz

doi:10.1039/9781782622536-00315

Doxils - the first fda-approved nano-drug: From basics via cmc, cell culture and animal studies to clinical use

Yechezkel Chezy Barenholz^*

^*Corresponding author for this work

Institute for Medical Research Israel-Canada (IMRIC)

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

14 Scopus citations

Abstract

Doxil^® was the first nano-drug to be approved by the US Food and Drug Administration and was developed through 7.5 years of major efforts in research, R&D, and development work as well as clinical studies by many people located in Jerusalem, in California, and in many hospitals worldwide that were involved in the various stages of Doxil^® clinical trials. Hadassah University Hospital was the site of the first Doxil^® clinical trial. The history of Doxil^® development is reviewed and the author describes in short the scientific highlights of the development of Doxil^® and the lessons learned from its 20 years of use, concentrating on the importance and relevance of cell culture studies. This chapter also discusses in short some of the new surprising findings from work on Doxil^®, which have not yet been published.

Original language	English
Title of host publication	Privileged Scaffolds in Medicinal Chemistry
Subtitle of host publication	Design, Synthesis, Evaluation
Editors	Martin Braddock, David Thurston
Publisher	Royal Society of Chemistry
Pages	315-345
Number of pages	31
Edition	51
DOIs	https://doi.org/10.1039/9781782622536-00315
State	Published - 2016

Publication series

Name	RSC Drug Discovery Series
Number	51
Volume	2016-January
ISSN (Print)	2041-3203
ISSN (Electronic)	2041-3211

Bibliographical note

Publisher Copyright:
© The Royal Society of Chemistry 2016.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1039/9781782622536-00315

Cite this

Barenholz, Y. C. (2016). Doxils - the first fda-approved nano-drug: From basics via cmc, cell culture and animal studies to clinical use. In M. Braddock, & D. Thurston (Eds.), Privileged Scaffolds in Medicinal Chemistry: Design, Synthesis, Evaluation (51 ed., pp. 315-345). (RSC Drug Discovery Series; Vol. 2016-January, No. 51). Royal Society of Chemistry. https://doi.org/10.1039/9781782622536-00315

@inbook{5283af9f9cb54c689f141ec0349a6b21,

title = "Doxils - the first fda-approved nano-drug: From basics via cmc, cell culture and animal studies to clinical use",

abstract = "Doxil{\textregistered} was the first nano-drug to be approved by the US Food and Drug Administration and was developed through 7.5 years of major efforts in research, R\&D, and development work as well as clinical studies by many people located in Jerusalem, in California, and in many hospitals worldwide that were involved in the various stages of Doxil{\textregistered} clinical trials. Hadassah University Hospital was the site of the first Doxil{\textregistered} clinical trial. The history of Doxil{\textregistered} development is reviewed and the author describes in short the scientific highlights of the development of Doxil{\textregistered} and the lessons learned from its 20 years of use, concentrating on the importance and relevance of cell culture studies. This chapter also discusses in short some of the new surprising findings from work on Doxil{\textregistered}, which have not yet been published.",

author = "Barenholz, \{Yechezkel Chezy\}",

note = "Publisher Copyright: {\textcopyright} The Royal Society of Chemistry 2016.",

year = "2016",

doi = "10.1039/9781782622536-00315",

language = "אנגלית",

series = "RSC Drug Discovery Series",

publisher = "Royal Society of Chemistry",

number = "51",

pages = "315--345",

editor = "Martin Braddock and David Thurston",

booktitle = "Privileged Scaffolds in Medicinal Chemistry",

address = "בריטניה",

edition = "51",

}

Barenholz, YC 2016, Doxils - the first fda-approved nano-drug: From basics via cmc, cell culture and animal studies to clinical use. in M Braddock & D Thurston (eds), Privileged Scaffolds in Medicinal Chemistry: Design, Synthesis, Evaluation. 51 edn, RSC Drug Discovery Series, no. 51, vol. 2016-January, Royal Society of Chemistry, pp. 315-345. https://doi.org/10.1039/9781782622536-00315

Doxils - the first fda-approved nano-drug: From basics via cmc, cell culture and animal studies to clinical use. / Barenholz, Yechezkel Chezy.
Privileged Scaffolds in Medicinal Chemistry: Design, Synthesis, Evaluation. ed. / Martin Braddock; David Thurston. 51. ed. Royal Society of Chemistry, 2016. p. 315-345 (RSC Drug Discovery Series; Vol. 2016-January, No. 51).

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

TY - CHAP

T1 - Doxils - the first fda-approved nano-drug

T2 - From basics via cmc, cell culture and animal studies to clinical use

AU - Barenholz, Yechezkel Chezy

PY - 2016

Y1 - 2016

N2 - Doxil® was the first nano-drug to be approved by the US Food and Drug Administration and was developed through 7.5 years of major efforts in research, R&D, and development work as well as clinical studies by many people located in Jerusalem, in California, and in many hospitals worldwide that were involved in the various stages of Doxil® clinical trials. Hadassah University Hospital was the site of the first Doxil® clinical trial. The history of Doxil® development is reviewed and the author describes in short the scientific highlights of the development of Doxil® and the lessons learned from its 20 years of use, concentrating on the importance and relevance of cell culture studies. This chapter also discusses in short some of the new surprising findings from work on Doxil®, which have not yet been published.

AB - Doxil® was the first nano-drug to be approved by the US Food and Drug Administration and was developed through 7.5 years of major efforts in research, R&D, and development work as well as clinical studies by many people located in Jerusalem, in California, and in many hospitals worldwide that were involved in the various stages of Doxil® clinical trials. Hadassah University Hospital was the site of the first Doxil® clinical trial. The history of Doxil® development is reviewed and the author describes in short the scientific highlights of the development of Doxil® and the lessons learned from its 20 years of use, concentrating on the importance and relevance of cell culture studies. This chapter also discusses in short some of the new surprising findings from work on Doxil®, which have not yet been published.

UR - https://www.scopus.com/pages/publications/84974800477

U2 - 10.1039/9781782622536-00315

DO - 10.1039/9781782622536-00315

M3 - ???researchoutput.researchoutputtypes.contributiontobookanthology.chapter???

AN - SCOPUS:84974800477

T3 - RSC Drug Discovery Series

SP - 315

EP - 345

BT - Privileged Scaffolds in Medicinal Chemistry

A2 - Braddock, Martin

A2 - Thurston, David

PB - Royal Society of Chemistry

ER -

Doxils - the first fda-approved nano-drug: From basics via cmc, cell culture and animal studies to clinical use

Abstract

Publication series

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this